19 results about "Non enveloped virus" patented technology

The invention relates to multiple preparation processes for targeted treatment of a class of non-enveloped virus nucleic acid or early-stage difficult-to-diagnose epidemic situation control. The key point is that different epidemic situations caused by enveloped or non-enveloped viruses are summarized and recognized from thousands of viruses and epidemic situations which are erupted all the time; the light is adopted to activate the methylene blue riboflavin, so that a plurality of enveloped viruses and a plurality of non-enveloped viruses can be respectively inactivated; the light-activated methylene blue riboflavin can be embedded into a virus nucleic acid chain to prevent replication so as to achieve targeted therapy, and the light-activated methylene blue riboflavin compound preparation is firstly used for treatment when virus types are difficult to diagnose in the early stage of an epidemic situation. In order to control epidemic situation propagation as soon as possible, after it is confirmed that enveloped virus infection or non-enveloped virus infection exists, light-activated methylene blue and a light-activated riboflavin preparation are adopted for targeted therapy. The light-activated methylene blue is adopted for treating three or five positive cases of hepatitis B once every two days by 120 milligrams every time, and all the cases are effectively turned to negative. The preparation process comprises the step of preparing the photoactivated methylene blue riboflavin and the capsule of the photoactivated methylene blue riboflavin.

To provide a virus inactivation composition having a high inactivating effect against non-enveloped viruses.SOLUTION: A composition for inactivating non-enveloped viruses, comprising (a) monoethanolamine, (b) an aromatic alcohol, and water, and having a pH of 10.5 or more and 14 or less at 25°C.SELECTED DRAWING: None

Disclosed herein are modified capsid proteins comprising a capsid forming protein, a membrane binding element and an ESCRT-recruiting element, wherein at least one of the membrane binding element and the ESCRT-recruiting element is heterologous to the capsid forming protein. Disclosed are capsids comprising a plurality of modified capsid proteins. Disclosed are multimeric assemblies comprising a plurality of capsids within a membrane. Also disclosed are modified non-enveloped viruses comprising a capsid wherein the capsid comprises a plurality of modified capsid proteins, wherein the plurality of modified capsid proteins comprise a capsid forming protein, a membrane binding element and an ESCRT-recruiting element, wherein at least one of the membrane binding element and the ESCRT-recruiting element is heterologous to the modified capsid protein, wherein the capsid forming protein is a capsid forming protein of a non-enveloped virus.

A pre-saturated wipe product is disclosed that is well suited for destroying non-enveloped viruses, including norovirus. The wipe composition includes a first antimicrobial agent blended with a second agent, such as a preservative. The wipe product can destroy and kill non-enveloped viruses completely in a relatively short contact time, even at very low concentrations in the wipe composition.

The present invention provides a disinfectant composition that is excellent in suppressing skin irritation and has a good effect in inactivating non-enveloped viruses, an article impregnated with the disinfectant composition, a method for inactivating non-enveloped viruses, and a method for producing the disinfectant composition. [Solution] A disinfectant composition containing (A) 40% to 95% by mass of ethanol, (B) 0.20% to 3.0% by mass of one or more selected from gluconic acid and its alkali metal salts, and (C) 0.10% to 2.0% by mass of a water-soluble polyhydric alcohol, with a pH of 5.0 or less at 25°C.

The present invention provides a method of inactivating enveloped viruses during the production of a biologic product without harming the biologic product. The method comprises contacting cells containing the biologic product with at least one purified non-ionic detergent, wherein the detergent(s) lyses the cells to release the biologic product, thereby producing a lysate, and wherein the detergent(s) inactivates any enveloped viruses within the lysate. The detergent can be an ethoxylated alcohol, sorbiton ethoxylate, triblock copolymer and combinations thereof. Examples of biologic products include non-enveloped viruses and therapeutic recombinant proteins produced via lysis of mammalian or insect cells.

To provide a virus inactivator that exhibits a viral inactivation effect for envelope viruses and also exhibits a superior viral inactivation effect for non-envelope viruses.SOLUTION: A virus inactivator comprising a phytic acid and at least one of the following component (A) and component (B). Component (A): at least one alkanediol selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, and 1,2-decanediol. Component (B): at least one oily component selected from the group consisting of lavender oil, camphor leaf oil, rosemary oil, peppermint oil, copaiba oil, squalane, and liquid paraffin.SELECTED DRAWING: None

The present invention relates to the fields of medicine, gene therapy and medicine, in particular to pharmaceutical compositions of vectors based on recombinant non-enveloped viruses, in particular recombinant adeno-associated viruses (rAVVs), which can be used to treat and prevent various diseases.

The invention relates to a methylene blue preparation technology for controlling epidemic outbreak through enveloped virus gene targeted therapy. The key point is that different epidemic situations caused by enveloped viruses or non-enveloped viruses are summarized and recognized from thousands of viruses and epidemic situations which are emerged all the time. The enveloped virus can be effectively inactivated by adopting light to activate methylene blue. The methylene blue can be embedded into a virus nucleic acid chain through light activation, and virus nucleic acid replication can be prevented, so that inactivation targeted therapy is achieved. The method is a breakthrough for controlling outbreak of epidemic situation in epidemic situation treatment. According to the preliminary result, the No.2 preparation of the light activated methylene blue is orally taken once every two days, and 120 milligrams of the No.2 preparation are taken each time. 15 times of treatment, all three or five positive cases of hepatitis B can be effectively turned to negative, and various preparations No.1 and No.3 have no obvious effect. The preparation process determines the curative effect. An effective way for treating and controlling propagation is explored for controlling threats to human life caused by epidemic situation propagation and outbreak. The preparation process comprises the steps of preparing the photo-activated methylene blue and the capsules, tablets and granules of the photo-activated methylene blue.

A composite quaternary ammonium salt disinfectant includes a double long-chain quaternary ammonium salt, two single long-chain quaternary ammonium salts, a synergist isothiazolinone, a nonionic surfactant fatty alcohol polyvinyl ether, and water, wherein the double long-chain quaternary ammonium salt is dialkyl dimethyl ammonium chloride with dialkyl being two independent alkyl groups with a chain length of C8-C18, and the two single-chain quaternary ammonium salts are alkyl dimethyl benzyl ammonium chloride with an alkyl chain length of C8-C18 and alkyl dimethyl ethyl benzyl ammonium chloride with an alkyl chain length of C8-C18, respectively. The composite quaternary ammonium salt disinfectant has a synergistic effect among its components, which greatly improves the capacity of resisting interferences by hard water and organics; and can kill not only bacterial propagules, lipophilic viruses (enveloped viruses, such as novel coronavirus) and fungi, but also hydrophilic viruses (non-enveloped viruses).

Disclosed are a method and system for thermal stabilization of pharmaceutical formulations containing enveloped and nonenveloped viruses. The disclosed method of Rapid Room Temperature Aerosol Dehydration (RTAD) provides a scalable system for continuous dehydration of liquid pharmaceutical and biopharmaceutical formulations that provides thermal stabilization of biological drugs by converting liquid drugs into powder form, enabling their transportation, storage and handling at room temperature. The disclosed process can generate sprays / aerosols with droplets that are 100x smaller (0.2-20 μm) than existing spray drying technologies and perform dehydration, without applying heat, which mitigates the risk of damage of thermolabile biologicals and provides a significant reduction in energy requirements. The technology has demonstrated superiority of the system over traditional spray drying and freeze drying with respect to energy consumption, biological activity, scalability, powder solubility, particle size and size uniformity, and high-quality of produced inhalable and reconstitutable biologic formulations.

Provided are: a disinfectant composition having an excellent effect of suppressing hand roughness and having a good effect of inactivating a non-enveloped virus; a disinfectant composition-impregnated article; a non-enveloped virus inactivation method; and a method for producing a disinfectant composition.　A disinfectant composition, according to the present invention, contains: (A) 40-95 mass% of ethanol; (B) 0.20-3.0 mass% of one or more substances selected from gluconic acid and alkali metal salts thereof; and (C) 0.10-2.0 mass% of a water-soluble polyhydric alcohol, and has a pH of 5.0 or less at 25°C.

Provided is an antiviral composition that has a photocatalytic function, and exhibits high antiviral activities against non-enveloped viruses that have been so far difficult to inactivate using a silver compound in a dark place not exposed to the light. This antiviral composition contains two types of particles that are photocatalyst particles and silver nanoparticles having a protection agent adsorbed on the surfaces thereof and having a dispersed particle diameter of 1000 nm or less and a primary particle diameter of 500 nm or less. The antiviral activity value, based on JIS R1756:2020, of the composition in a dark place is greater than 0.3, and the antiviral activity value of the composition brought by irradiation with light based on JIS R1756:2020 is at least 0.3.

The invention discloses an acidic hydrogen peroxide alcohol hand disinfectant and a preparation method thereof, and relates to the technical field of disinfectants. The cleaning agent is prepared from the following components in percentage by mass: 0.1-3% of hydrogen peroxide, 0.05-1% of an acidity enhancer, 50-80% of an alcohol substance, 0.1-3% of glycerol, 0.1-5% of a film-forming agent, 0.1-2% of a repairing component, 0.02-1% of a stabilizer and the balance of deionized water, wherein the acidity enhancer is citric acid, lactic acid or malic acid, the film-forming agent is tara gum, tamarind gum or a sodium alginate derivative, and the repairing component is a plant stem cell extract, an acid algae extract or a sargassum muticum extract. According to the invention, three problems that a low-concentration hydrogen peroxide hand disinfectant, an alcohol hand disinfectant and a hydrogen peroxide quick-drying hand disinfectant cannot achieve an inactivation effect on non-enveloped viruses in the presence of organic pollutants, skin irritation is easily caused, and hydrogen peroxide is easily decomposed and fails in a system are solved.

The present invention relates to the field of pharmaceuticals, gene therapy and medicine, specifically to pharmaceutical compositions of a vector based on recombinant non-enveloped virus, in particular recombinant adeno-associated virus (rAAV), which compositions may be used for the treatment and prophylaxis of various diseases.

A method for flow cytometry evaluation of unassociated non-enveloped viral particles having a non-enveloped viral capsid includes preparing a fluorescently-stained fluid sample in which at least one fluorescent staining step is performed at an acidic pH in an acidic pH range and then subjecting the fluorescently-stained fluid sample to flow cytometry evaluation. A kit includes a plurality of sealed container with a first sealed container containing a fluorescent stain composition and a second sealed container including an aqueous dilution liquid at an acidic pH.

The present invention provides an antiviral decorative sheet which maintains the surface properties of a surface protective layer and which is capable of exerting an antiviral effect even on nonenveloped viruses. Specifically, the antiviral decorative sheet of the present invention has a crosslinking and curing type resin layer in the outermost surface layer, and is characterized in that: (1) the crosslinking and curing type resin layer contains a cured product of a crosslinking and curing type resin and an antiviral agent; and (2) the antiviral agent has antiviral properties against nonenveloped viruses, and contains a carboxylic acid derivative and a styrene polymer derivative, and contains all of triethylamine, N,N-dimethylallylamine, dimethylpyrrole, tetramethyl-1,3-propanediamine and N,N,2,2-tetramethyl-1,3-propanediamine as constituent components of the carboxylic acid derivative.

Disclosed is an air purification product comprising an air purification formulation and a pressurized gas of about 60 psig or more in an aerosol can comprising a two-piece mechanical decomposition (MB) nozzle having a swirl chamber. The air purification formulation includes from about 10% to about 43% dipropylene glycol by weight of the formulation. The MB nozzle includes two rod bores, each having a diameter of about 0.036 inches [0.91 mm] to about 0.044 inches [1.12 mm]. The disclosed air purification formulation can disinfect and sterilize air having a volume less than or equal to 25 m3 within 0.1 to 5 minutes by reducing aerosol bacteria (including Staphylococcus aureus and Klebsiella pneumoniae) and aerosol enveloped viruses (including Phi6) by an amount equal to or greater than 3 log10. The aerosol non-enveloped virus (such as MS2) is reduced by 3 log10 within 10-15 minutes.